Thank you, Madam Chair.
I think this is actually a really important initiative, and it's a really good example of how the federal government can play its role in collaboration not only with the provinces and territories, but also with other partners, basically to get information earlier and more comprehensively on the impact of drugs in the marketplace. It's consistent with the approach we want to take to have a life-cycle approach to drugs. Rather than simply approving them at the front end, we want to actually monitor the performance of pharmaceuticals in the marketplace, as we get more and better information. In fact, we expect to be issuing the first call for projects on the drug safety and effectiveness network this autumn.